A 56-year-old woman is referred to the gastrointestinal clinic for evaluation of persistently elevated liver enzyme levels. Her medical history is significant for obesity, hypertension, dyslipidemia, obstructive sleep apnea, and type 2 diabetes mellitus. Medications include metformin, semaglutide, atorvastatin, and lisinopril. She drinks alcohol only on rare social occasions. Vital signs are within normal limits. Physical examination demonstrates central obesity. Laboratory studies show the following:
AST: 68 U/L
ALT: 82 U/L
Total bilirubin: 0.8 mg/dL
Hepatitis B surface antigen: negative
Hepatitis C antibody: negative
Abdominal ultrasonography demonstrates diffuse hepatic steatosis. Which of the following is the most appropriate initial management?
The correct answer is:
B) Lifestyle modification with weight loss
This patient has metabolic dysfunction-associated steatotic liver disease with evidence of steatohepatitis (MASH). Multiple clues support the diagnosis, including obesity, type 2 diabetes, dyslipidemia, mild transaminase elevation, and hepatic steatosis on imaging. The absence of significant alcohol use and negative viral hepatitis testing further support a metabolic etiology.
MASH represents the progressive inflammatory form of steatotic liver disease and may eventually lead to fibrosis, cirrhosis, portal hypertension, and hepatocellular carcinoma. Weight reduction remains the cornerstone of therapy. A weight loss of approximately 7%–10% can significantly improve hepatic inflammation and histologic disease activity. Management also includes aggressive treatment of metabolic risk factors such as diabetes, obesity, hypertension, and dyslipidemia.
Answer choice A: Immediate liver transplantation evaluation, is incorrect.
Liver transplantation is reserved for patients with advanced liver failure or decompensated cirrhosis. This patient has early-stage disease.
Answer choice C: Long-term corticosteroid therapy, is incorrect.
Corticosteroids are not standard first-line therapy for MASH and are more commonly used in autoimmune hepatitis.
Answer choice D: Therapeutic phlebotomy, is incorrect.
Phlebotomy is the treatment of choice for hereditary hemochromatosis, a disorder of iron overload.
Answer choice E: Ursodeoxycholic acid therapy, is incorrect.
Ursodeoxycholic acid is used in primary biliary cholangitis and does not represent first-line therapy for MASH.
Key Learning Point
MASH is strongly associated with obesity, diabetes, and metabolic syndrome. Weight loss and treatment of metabolic risk factors remain the most effective initial interventions.
